Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome.
In two double-blind, placebo-controlled clinical studies of the nootropic compound acetyl-L-carnitine on the electroencephalogram (EEG) and impaired brain functions of elderly outpatients with mild to moderate cognitive decline of the organic brain syndrome, statistically significant effects could be detected after eight weeks (on the EEG), and after 12 weeks of treatment (on the physician's clinical global impression and the patient-rated level of activities of daily living). Side-effects of acetyl-L-carnitine were generally minor and overall rare. Longer treatment periods and further specifications with regard to the aetiopathology and degree of cognitive impairment are recommended for further clinical studies of this promising compound.
Herrmann
W M
WM
Department of Clinical Psychiatry, Free University, Berlin, Federal Republic of Germany.
Dietrich
B
B
Hiersemenzel
R
R
D000108:Acetylcarnitine / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D002331:Carnitine / Q000031:analogs & derivatives*; D004311:Double-Blind Method; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019965:Neurocognitive Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D016032:Randomized Controlled Trials as Topic
D000108:Acetylcarnitine; D002331:Carnitine